Mycoapaisyl (Econazole Nitrate)

Econazole nitrate blocks the fungal enzyme lanosterol 14α‑demethylase, which is essential for synthesising ergosterol, a key component of the fungal cell membrane. By preventing ergosterol formation, the drug disrupts membrane integrity, leading to increased permeability and ultimately fungal cell death.

The dosage and frequency of Mycoapaisyl are determined by the prescribing healthcare professional based on the type and severity of the infection, the patient’s age and the area of skin involved. Patients should follow the prescriber’s instructions and the product label.

Safety data for econazole nitrate in pregnancy and lactation are limited, and the product’s classification is not specified. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Mycoapaisyl to pregnant or nursing individuals.

To request Mycoapaisyl, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Econazole nitrate belongs to the imidazole class and offers broad‑spectrum activity against dermatophytes and yeasts. Compared with allylamine agents such as terbinafine, econazole has a similar efficacy for many superficial infections but may differ in dosing frequency and potential for local irritation. Choice of therapy should be guided by the specific pathogen, infection site and patient tolerance.

Mycoapaisyl should be stored at room temperature, preferably below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct sunlight to maintain product stability.

The cream or ointment is applied thinly to the affected skin area, usually twice daily, after washing and gently drying the site. The medication should be rubbed in gently until fully absorbed, and hands should be washed after application to avoid inadvertent contact with eyes or mucous membranes.

Although uncommon, serious adverse reactions can include severe allergic responses such as urticaria, angio‑edema, or anaphylaxis, as well as extensive skin rash or exfoliative dermatitis. Patients should discontinue use and seek immediate medical attention if they experience swelling, difficulty breathing, or widespread skin eruptions.

Mycoapaisyl should not be used on broken, inflamed or infected skin that is not of fungal origin, nor should it be applied to the eyes, mucous membranes or genital mucosa. Individuals with a known hypersensitivity to econazole nitrate or any component of the formulation should avoid its use.